I can give you a few examples but it is only a few.
There have been global companies that have taken out Aussie biotechs - Cellestis and Qiagen, Cephalon and Chemgenex.
Also large licensing deals from Eli Lilly with Acrux, Cephalon with Mesoblast.
But I guess these have generally been at later stages and that would make sense for an international company looking to takeover an Australian one (if they only have a small presence here though I guess good advisers negate that somewhat).
I personally believe we'll see activity this year and the next from Big Pharma with Aussie biotechs. I think Alchemia have a good chance of partnering with Big Pharma with a decent deal through their HyACT platform and also Immuron with their NASH therapeutic (I hold both).
